General Information of Drug (ID: DMDSZNC)

Drug Name
INCAGN2385
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Phase 1 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
D4KTA9

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lymphocyte activation gene 3 protein (LAG3) TTNVXAW LAG3_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04370704) Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Agenus.